WO2004069203A3 - Oral compositions of fenretinide having increased bioavailability and methods of using the same - Google Patents

Oral compositions of fenretinide having increased bioavailability and methods of using the same Download PDF

Info

Publication number
WO2004069203A3
WO2004069203A3 PCT/US2004/003562 US2004003562W WO2004069203A3 WO 2004069203 A3 WO2004069203 A3 WO 2004069203A3 US 2004003562 W US2004003562 W US 2004003562W WO 2004069203 A3 WO2004069203 A3 WO 2004069203A3
Authority
WO
WIPO (PCT)
Prior art keywords
fenretinide
methods
same
oral compositions
increased bioavailability
Prior art date
Application number
PCT/US2004/003562
Other languages
French (fr)
Other versions
WO2004069203A2 (en
Inventor
Barry James Maurer
C Patrick Reynolds
David W Yesair
Robert Travis Mckee
Stephen W Burgess
Walter A Shaw
Original Assignee
Los Angeles Childrens Hospital
Barry James Maurer
C Patrick Reynolds
David W Yesair
Robert Travis Mckee
Stephen W Burgess
Walter A Shaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital, Barry James Maurer, C Patrick Reynolds, David W Yesair, Robert Travis Mckee, Stephen W Burgess, Walter A Shaw filed Critical Los Angeles Childrens Hospital
Priority to EP04706566.9A priority Critical patent/EP1594544B1/en
Priority to CA2513260A priority patent/CA2513260C/en
Priority to ES04706566.9T priority patent/ES2581184T3/en
Priority to JP2006503401A priority patent/JP2006518384A/en
Priority to DK04706566.9T priority patent/DK1594544T3/en
Priority to MXPA05008138A priority patent/MXPA05008138A/en
Publication of WO2004069203A2 publication Critical patent/WO2004069203A2/en
Publication of WO2004069203A3 publication Critical patent/WO2004069203A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals

Abstract

The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.
PCT/US2004/003562 2003-01-31 2004-01-29 Oral compositions of fenretinide having increased bioavailability and methods of using the same WO2004069203A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP04706566.9A EP1594544B1 (en) 2003-01-31 2004-01-29 Oral compositions of fenretinide having increased bioavailability and methods of using the same
CA2513260A CA2513260C (en) 2003-01-31 2004-01-29 Oral compositions of fenretinide having increased bioavailability and methods of using the same
ES04706566.9T ES2581184T3 (en) 2003-01-31 2004-01-29 Oral phenretinide compositions that have greater bioavailability and methods of use thereof
JP2006503401A JP2006518384A (en) 2003-01-31 2004-01-29 Oral composition of fenretinide with improved bioavailability and method of use thereof
DK04706566.9T DK1594544T3 (en) 2003-01-31 2004-01-29 ORAL COMPOSITIONS OF FENRETINIDE WHICH HAVE INCREASED BIOTAILABILITY AND PROCEDURES FOR USING IT
MXPA05008138A MXPA05008138A (en) 2003-01-31 2004-01-29 Oral compositions of fenretinide having increased bioavailability and methods of using the same.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44453003P 2003-01-31 2003-01-31
US60/444,530 2003-01-31

Publications (2)

Publication Number Publication Date
WO2004069203A2 WO2004069203A2 (en) 2004-08-19
WO2004069203A3 true WO2004069203A3 (en) 2005-02-03

Family

ID=32850878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003562 WO2004069203A2 (en) 2003-01-31 2004-01-29 Oral compositions of fenretinide having increased bioavailability and methods of using the same

Country Status (9)

Country Link
US (3) US7785621B2 (en)
EP (1) EP1594544B1 (en)
JP (1) JP2006518384A (en)
CA (1) CA2513260C (en)
DK (1) DK1594544T3 (en)
ES (1) ES2581184T3 (en)
MX (1) MXPA05008138A (en)
PT (1) PT1594544T (en)
WO (1) WO2004069203A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014978A (en) 2004-06-23 2007-04-25 Sirion Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives.
US7432307B2 (en) 2004-11-04 2008-10-07 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
EP1688049A1 (en) * 2005-02-03 2006-08-09 findusFit Sportdiätetika GmbH Dietary foodstuff
EP1959945B1 (en) * 2005-12-13 2014-12-03 McGill University Fenretinide for correcting a lipid imbalance in a subject
NZ572601A (en) 2006-03-29 2012-03-30 Univ Wayne State Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2009033768A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2244702B1 (en) 2008-02-21 2014-09-17 The Royal Institution for the Advancement of Learning/McGill University Treatment of neural diseases or conditions
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9622500B2 (en) 2008-11-04 2017-04-18 The Quaker Oats Company Food products prepared with soluble whole grain oat flour
US9504272B2 (en) 2008-11-04 2016-11-29 The Quaker Oats Company Method of processing oats to achieve oats with an increased avenanthramide content
US10980244B2 (en) 2008-11-04 2021-04-20 The Quaker Oats Company Whole grain composition comprising hydrolyzed starch
US9510614B2 (en) 2008-11-04 2016-12-06 The Quaker Oats Company Food products prepared with soluble whole grain oat flour
US10689678B2 (en) 2008-11-04 2020-06-23 The Quaker Oats Company Method and composition comprising hydrolyzed starch
EP2352505B1 (en) 2008-11-04 2016-07-06 University Of Kentucky Research Foundation D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
WO2011059776A2 (en) * 2009-10-28 2011-05-19 Revision Therapeutics, Inc Prophylaxis of skin cancer with retinamides
EP2640368B1 (en) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2012068169A2 (en) * 2010-11-15 2012-05-24 Texas Tech University Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments
CA2820960A1 (en) 2010-12-29 2012-07-05 Abbott Laboratories Nutritional products including a novel fat system including monoglycerides
BR112013024263A2 (en) 2011-03-21 2016-12-27 Pepsico Inc method for preparing rdt high acid whole grain drinks
BR112014002956A8 (en) 2011-07-12 2022-09-06 Pepsico Inc METHOD OF PREPARING A MILK DRINK CONTAINING OATS
US20130295227A1 (en) * 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
US10057726B2 (en) * 2012-10-02 2018-08-21 Razer (Asia-Pacific) Pte. Ltd. Managing user data on an electronic device
US20150283083A1 (en) * 2012-11-19 2015-10-08 Azanta A/S Dispersible Tablet
US20170275662A1 (en) 2016-03-22 2017-09-28 The Quaker Oats Company Method and Apparatus for Controlled Hydrolysis
US11172695B2 (en) 2016-03-22 2021-11-16 The Quaker Oats Company Method, apparatus, and product providing hydrolyzed starch and fiber

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US20020183394A1 (en) * 2000-12-05 2002-12-05 Shanker Gupta Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI783405A (en) * 1977-12-22 1979-06-23 Stamag INTERESTED FACILITIES FOR THE PURPOSE OF FURNITURE
DE3119383A1 (en) * 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen METHOD FOR PRODUCING FINE DISTRIBUTED, POWDERED CAROTINO PREPARATIONS
JPS59137410A (en) * 1983-01-27 1984-08-07 Riken Vitamin Co Ltd Preparation of stable powdery vitamin a
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US5002779A (en) * 1989-11-07 1991-03-26 The Procter & Gamble Company Dry stable chocolate beverage containing iron and vitamin C
WO1992003121A1 (en) * 1990-08-13 1992-03-05 Yesair David W Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
US5891466A (en) 1990-08-13 1999-04-06 Yesair; David W. Mixed Liped-Bicarbonate colloidal particles for delivering drugs or calories
WO1992019251A1 (en) * 1991-05-06 1992-11-12 The Procter & Gamble Company Combined calcium and vitamin d supplements
US6159503A (en) 1993-12-02 2000-12-12 Hercules Incorporated Pectin process and composition
JPH0867666A (en) * 1994-08-29 1996-03-12 Lion Corp Powdery pharmaceutical preparation containing carotenoid and its production
CA2222161C (en) * 1995-06-06 2002-02-05 Biomolecular Products, Inc. Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
DE69821520T2 (en) 1997-11-10 2004-12-16 G.D. Searle & Co., Chicago USE OF ALKYLATED IMINO SUGARS FOR THE TREATMENT OF MULTIPLE MEDICINE RESISTANCE
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
ES2316188T3 (en) * 1998-06-29 2009-04-01 Children's Hospital Los Angeles TREATMENT OF HYPERPROLIFERATIVE DISORDERS.
JP4700193B2 (en) * 1998-09-08 2011-06-15 バイオモレキュラー・プロダクツ・インコーポレーテッド Methods and compositions for increasing intestinal absorption of fat
BR9914079A (en) * 1998-09-29 2001-06-19 Procter & Gamble Low-acid drinks supplemented with nutritional calcium sources
JP2001103930A (en) * 1999-10-08 2001-04-17 Kikkoman Corp Isoflavone compound-enriched food
EP1328262A2 (en) * 2000-10-17 2003-07-23 Board of Regents, The University of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
AU2002235175A1 (en) 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
EP1434593B1 (en) 2001-10-11 2017-03-29 Biomolecular Products, Inc. MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US20020183394A1 (en) * 2000-12-05 2002-12-05 Shanker Gupta Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same

Also Published As

Publication number Publication date
US7780978B2 (en) 2010-08-24
CA2513260A1 (en) 2004-08-19
DK1594544T3 (en) 2016-07-25
CA2513260C (en) 2013-01-08
EP1594544B1 (en) 2016-04-06
WO2004069203A2 (en) 2004-08-19
US20050271707A1 (en) 2005-12-08
MXPA05008138A (en) 2006-02-17
US20060008508A1 (en) 2006-01-12
ES2581184T3 (en) 2016-09-01
US20050106216A1 (en) 2005-05-19
PT1594544T (en) 2016-07-14
US7785621B2 (en) 2010-08-31
EP1594544A2 (en) 2005-11-16
JP2006518384A (en) 2006-08-10
EP1594544A4 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
WO2004069203A3 (en) Oral compositions of fenretinide having increased bioavailability and methods of using the same
EP2279732A3 (en) Compounds and compositions for delivering active agents
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
MX343314B (en) Multi-functional ionic liquid compositions.
HK1096034A1 (en) A solid dosage form comprising a fibrate
MXPA05012191A (en) Liquid stabilized protein formulations in coated pharmaceutical containers.
EA200600479A1 (en) PHARMACEUTICAL COMPOSITION, INCLUDING LANTHANE COMPOUNDS
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2006050533A3 (en) Stabilized individually coated ramipril particles, compositions and methods
HK1083200A1 (en) Pharmaceutical preparations for oral administration, containing ion- exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
IL179718A0 (en) Pharmaceutical composition containing irbesartan
WO2006040112A3 (en) Taste-masking pharmaceutical compositions
WO2007016388A3 (en) Liquid formulations for controlled delivery of benzisoxazole derivatives
WO2006102990A3 (en) Tablet containing steroid hormones
GB2443793B (en) Product, method of manufacture and use
HRP20050342B1 (en) Pharmaceutical formulation of olanzapine
PL1827136T3 (en) Formulation for oral administration having a health-promoting effect on the cardiovascular system
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
JP2005002005A (en) Coenzyme q10-containing composition
WO2003045305A3 (en) Acetaminophen compositions
TW200420304A (en) Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2513260

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/008138

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006503401

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004706566

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004706566

Country of ref document: EP